Clinical Trials Logo

Fibrosis clinical trials

View clinical trials related to Fibrosis.

Filter by:

NCT ID: NCT04297709 Completed - Cystic Fibrosis Clinical Trials

Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis

SUPERB-CF
Start date: February 1, 2018
Phase:
Study type: Observational

Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis

NCT ID: NCT04293926 Completed - Clinical trials for Cystic Fibrosis in Children

Heart Rate Variability in Children and Adolescents With Cystic Fibrosis

Start date: March 5, 2020
Phase: N/A
Study type: Interventional

This study aims to assess the effects of a resistance exercise training program on heart rate variability in a group of children and adolescents with cystic fibrosis. The study design is a randomized controlled trial.

NCT ID: NCT04279769 Completed - Cystic Fibrosis Clinical Trials

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Start date: July 3, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.

NCT ID: NCT04279197 Completed - Clinical trials for Pulmonary Fibrosis Due to COVID-19

Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu

Start date: April 23, 2020
Phase: Phase 2
Study type: Interventional

According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can affect patients'lung function and even life health.This study aims to observe the efficacy and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.

NCT ID: NCT04277819 Completed - Cystic Fibrosis Clinical Trials

The Use of Novel Diagnostic Tools to Increase Detection of Early Fibrosis in Cystic Fibrosis Related Liver Disease to Improve Clinical Management

Start date: February 15, 2019
Phase:
Study type: Observational [Patient Registry]

Cystic Fibrosis (CF) is a genetic condition which affects 1 in 2500 newborn infants and is the commonest genetic condition in the UK. 1 in 25 of the white population carry the mutation. The genetic defect prevents the movement of fluids from cells, leading to thickened secretions and injury. With improvements in treatments from the commonest organ affected, the lungs, patients born with CF now can expect to live into their 40s with more than 60% living past 16. Though better, more can be done. As treatments from lung complications have improved, the management of liver disease (second commonest organ involved) remains unchanged for a considerable time. Treatment options are limited with liver transplant the only curative option. Though potentially life-saving, it has risks and an organ shortage means alternative treatment options are desperately needed. Identifying those with or at risk of Cystic Fibrosis related liver disease is difficult due to inadequate diagnostic tools. Routine blood tests are unreliable; therefore specific blood tests to identify scarring of the liver (biomarkers) are urgently needed. Ultrasound scan, the recommended diagnostic investigation, is only accurate in identifying the late stages of liver disease. For new therapies to be most effective we need to be able to identify patients at a much earlier stage. This study will use multi-modality testing, including imaging techniques such as FibroScan, MRI scan and blood tests (biomarkers), to diagnose those with liver scarring and use this to better categorise disease.

NCT ID: NCT04267406 Completed - Cirrhosis, Liver Clinical Trials

ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension

Start date: January 2, 2019
Phase:
Study type: Observational

Hemostasis-related disorders are common in cirrhosis and portal hypertension. However, it is not known whether the net effect of changes in hemostasis in the sense of predisposition to hemorrhagic or thrombotic state. It is suggested that increasing the concentration and activities of Von Willebrand factor (vWF) and decline ADAMTS-13 (A Disintegrin and Metalloproteinase with Trombospondin type 1 motif, member 13) may cause thrombophilic changes in cirrhosis and portal hypertension. The aim of this study was to investigate the changes in ADAMTS-13 (A disintegrin and metalloproteinase with thrombospondin motifs 13) and von willebrand factor (vWF) levels and activities in patients with cirrhosis and portal hypertension.

NCT ID: NCT04259983 Completed - Cystic Fibrosis Clinical Trials

Investigation of Relationship Between Vascular Functions, Exercise Capacity, and Respiratory Functions in CF

Start date: April 11, 2022
Phase:
Study type: Observational [Patient Registry]

In the literature, there is no study that evaluates the endothelial function and arterial stiffness together and investigates its relationship with exercise capacity and respiratory functions in children with CF of different obstruction severities. Therefore, the aim of this study is to investigate and compare microvascular (endothelium), macrovascular (arterial stiffness) functions in children with CF of different obstruction severities, and to investigate the relationship between micro and macrovascular functions and exercise capacity and respiratory functions in children with CF of different obstruction severities.

NCT ID: NCT04249466 Completed - Cystic Fibrosis Clinical Trials

Diet, Physical Activity and Glucose Tolerance in Cystic Fibrosis. Exploratory Study.

MONA
Start date: June 5, 2020
Phase:
Study type: Observational

Background : Diabetes is correlated to an increase in patient morbidity and mortality. The pathophysiology of diabetes is still poorly understood. Significant variations in blood sugar have been shown over time in patients with cystic fibrosis with or without diabetes. No study has evaluated the association between the nutritional profile and the glucose tolerance in adult with cystic fibrosis, by integrating data on energy consumption (detailed nutritional profile) and energy expenditure (rest energy expenditure, body composition, and physical activity). Given the epidemiological changes in cystic fibrosis correlated to the increased prevalence of diabetes and the clinical impact of nutritional status, the association between these factors remains to be studied. Objectives of the study : - Main objective : To describe adult patients with cystic fibrosis in terms of : - Nutritional profile - Food behaviour - Physical activity - Rest energy expenditure - Body composition - Secondary objectives : To research the association between the nutritional profile and the glucose tolerance.

NCT ID: NCT04244487 Completed - Hypertension Clinical Trials

Laparoscopic Splenectomy and Azygoportal Disconnection With Intraoperative Endoscopic Variceal Ligation

SVEL
Start date: January 3, 2020
Phase: N/A
Study type: Interventional

This study aimed to evaluate whether synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation (SVEL) is effective and safe, and to determine whether SVEL can effectively decrease the incidence of postoperative esophageal variceal re-bleeding.

NCT ID: NCT04243681 Completed - Cirrhosis, Liver Clinical Trials

Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis

Start date: July 1, 2019
Phase: Phase 4
Study type: Interventional

Though the results of autologous CD34+ cell infusion and MSC in independent studies have shown promise, yet they are yet to reach the desired long term outcome. The possible postulation for this is possibly because when using autologous CD34+ cell infusion, the inflammatory milieu of the liver may not be conducive for sustained effects of the mobilized CD 34+ cells. MSC have immunomodulatory effect (ref) and may improve the liver environment making it more beneficial for the CD34+ cells to function and survive. In addition, MSC has ben shown to produce hepatocyte growth factor which is protective against liver injury and beneficial for liver regeneration (shown in above tables). However, it remains to be understood how MSCs promote liver stem stem cells to differentiate into hepatocytes or expand the residual hepatocyte population. MSC can also directly inhibit the activation of hepatic stellate cells, the main source of extracellular matrix via MSC derived IL 10 and TNF-αand may also induce hepatic stellate cell apoptosis. Current lacunae in cell based therapy is based on the poor consensus and understanding on the best type of cells to be used, the ideal number of cells, the most appropriate route of administration and the need for repeat dosing . The concept that combination of autologous hematopoietic and mesenchymal stem cells infusion may be more beneficial than infusing any one of them alone has been discussed in many scientific forums but there are no study till date to either see the safety as well as the efficacy of this proof of concept . With this above background data, we propose a study design which will be a safety study for combination use of autologous CD34+ and MSC